Results 221 to 230 of about 182,514 (265)

Synergistic Remodeling of Tumor Immune Microenvironment via a DNA Nanodevice Integrating STING Activation and Lysosome‐Targeted PD‐L1 Degradation

Advanced Science, EarlyView.
A rational design DNA nanoplatform not only achieves efficient PD‐L1 degradation but also triggers robust STING signaling. The nanodevice effectively reprograms “cold” tumors, leading to potent inhibition of tumor growth and metastasis in vivo. ABSTRACT The cGAS‐STING pathway is a cornerstone of innate antitumor immunity; however, its therapeutic ...
Haoxiang Li, Min Hou, Shasha Sun, Jun Cao, Jian‐Hui Jiang, Jianjun He   +5 more
wiley   +1 more source

Precision immunotherapy in oesophageal squamous cell carcinoma: Molecular pathogenesis and checkpoint inhibitor response prediction. [PDF]

World J Gastrointest Pharmacol Ther
Chisthi MM, Viswanath S, Kuttanchettiyar KG.   +2 more
europepmc   +1 more source

Host Determinants of Immune Checkpoint Inhibitor Efficacy: Immune, Genetic, Metabolic, and Lifestyle Factors. [PDF]

Int J Mol Sci
Awada A, Charbel N, Faraj S, Hassan M, Awada D, Issa A, Nasr W, El Meski S, Hatahet Z, Tarhini A, Rizkallah J, Kreidieh F.   +11 more
europepmc   +1 more source

Mechanisms and biomarkers of immune checkpoint inhibitor-associated myocarditis: from T cell imbalance to multicellular crosstalk. [PDF]

Front Immunol
Huang J, Xu X, Jin Y, Qiao L, Yu H, Gao W, Li C.   +6 more
europepmc   +1 more source

Cardiac dysfunction during immune checkpoint inhibitor therapy: association with extracardiac immune-related adverse events. [PDF]

Cardiooncology
Mincu RI, Lampe L, Michel L, Mahabadi AA, Mark AV, Zimmer L, Livingstone E, Schadendorf D, Tasdogan A, Rassaf T, Totzeck M.   +10 more
europepmc   +1 more source

Immune Checkpoint Inhibitor-Associated Myocarditis With Multisystem Immune Toxicity in Renal Cell Carcinoma. [PDF]

JACC Case Rep
Chennuri RN, Madine M, Prathipati R, Mannam R, Reddy SR, Davala P, Chilana JK, Bari F.   +7 more
europepmc   +1 more source

Immune Checkpoint Inhibitor-Induced Sarcoidosis-Like Reaction Mimicking Pulmonary Metastasis: A Case Report. [PDF]

Cureus
Sawada M, Kurose Y, Ochi Y, Kanno K, Andou M.   +4 more
europepmc   +1 more source

Immune Checkpoint Inhibitor Therapy Associated Hypophysitis

Clinical Medicine Insights: Endocrinology and Diabetes, 2015
Moeber Mahzari, Dora Liu, Amel Arnaout, Heather Lochnan   +3 more
doaj  

Some of the next articles are maybe not open access.

Related searches:

Checkpoint inhibitors

Hematology, 2023
Abstract Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. These medications commonly cause immune-related adverse effects due to activated adaptive and innate immune cells, autoantibody production, and/or cytokine dysregulation.
openaire   +2 more sources

Immune Checkpoint Inhibitors in the Aged

Current Oncology Reports, 2021
Large phase III trials have established the benefit of checkpoint blockade across multiple tumor types, but patient representation is limited in some subgroups including the aged population. There are several changes in the immune system that occur with age (termed immunosenescence) that could potentially limit efficacy in aged populations.Despite the ...
James Isaacs, Scott Antonia, Jeffrey Clarke   +2 more
openaire   +2 more sources